<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04030065</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-livertransplant-01</org_study_id>
    <nct_id>NCT04030065</nct_id>
  </id_info>
  <brief_title>Study to Assess the Effect of Intravenous Supplementation of Omega-3 Fatty Acids on Outcome of Recipients in Living Donor Liver Transplantation</brief_title>
  <official_title>Randomized Controlled Trial to Study the Effect of Intravenous Supplementation of Omega-3 Fatty Acids on Outcome of Recipients in Living Donor Liver Transplantation (LDLT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators aim to analyse the effect of Omega 3 fatty acid
      supplementation on recipients undergoing living donor liver transplantation. In Group A, the
      patients receive Omega 3 fatty acid on preoperative day 1, intraoperatively and up to day 5
      post operatively; and the effect of omega 3 fatty acid supplementation on early allograft
      dysfunction, its correlation with occurrence of postoperative complications and liver
      regeneration measured by CT volumetry on Day 7. Group B, the patients are controls for the
      study and hence attempt to find out the effect of omega 3 fatty acid supplementation on
      outcome of recipients of Living donor liver transplantation. the investigators will analyse
      the data and elucidate the value of omega 3 fatty acid supplementation in reducing the
      occurrence of early allograft dysfunction , complications and effect on liver regeneration in
      recipients of Living donor liver transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Allograft Dysfunction</measure>
    <time_frame>Post operative day 7</time_frame>
    <description>To study the correlation with early allograft dysfunction using definition of early allograft dysfunction based on laboratory parameters (presence of one or more of the following : bilirubin &gt;or=10mg/dL on day 7, international normalized ratio &gt;or=1.6 on day 7, and alanine or aspartate aminotransferases &gt;2000 IU/L within the first 7 days)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver function test - trend</measure>
    <time_frame>Till period of hospital stay, average of 1 month</time_frame>
    <description>To study the correlation between supplementation of omega-3 fatty acids and trend in post-operative LFTs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Till period of hospital stay, average of 1 month</time_frame>
    <description>Post-operative complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital stay</measure>
    <time_frame>Till period of hospital stay, average of 1 month</time_frame>
    <description>To determine the total hospital stay and ICU stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Experimental Arm - omega 3 fatty acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm - No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3 fatty acid</intervention_name>
    <description>10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.</description>
    <arm_group_label>Experimental Arm - omega 3 fatty acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All elective liver transplant recipients

          -  Adult patients

          -  Those who consent

        Exclusion Criteria:

          -  Liver transplantation for fulminant hepatic failure

          -  Re-transplantation

          -  Known allergy to the study emulsion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viniyendra Pamecha, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Professor and head , Department of HPB surgery and liver Transplantation, ILBS, New Delhi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Senior Resident</last_name>
    <phone>+918800984217</phone>
    <email>vvkhere@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of liver and biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Senior Resident</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 21, 2019</last_update_submitted>
  <last_update_submitted_qc>July 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Liver and Biliary Sciences, India</investigator_affiliation>
    <investigator_full_name>Vivek Rajendran</investigator_full_name>
    <investigator_title>Senior Resident, Department of HPB surgery and Liver transplantation</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

